Some units from the Surgical Hospital are moving to Meilahti: Emergency Clinic for Ear, Nose, and Throat Diseases will become a part of Meilahti Emergency Department
28.1.2025 08:00:00 EET | HUS | Press release
The ear, nose, and throat diseases emergency clinic, urgent care during office hours, ward, and tumor outpatient clinic are moving from the Surgical Hospital to the Meilahti hospital campus. The units begin operating in the new location on February 4, 2025.

Emergency Clinic for Ear, Nose, and Throat Diseases will transfer to Meilahti Emergency Department
The Emergency Clinic for Ear, Nose, and Throat Diseases will become a part of the Meilahti Emergency Department. Access to Meilahti Emergency Department is via the Paciuksenkatu entrance to Bridge Hospital (Paciuksenkatu 3). In future, patients under the age of 16 in need of urgent care are treated at the emergency department of New Children's Hospital. Operation starts in the new premises on Tuesday, February 4, 2025, at 8 a.m.
An emergency referral from a doctor is required for treatment at the unit. If the patient does not have a referral or a previous treatment relationship with ear, nose, and throat diseases, we recommend calling the Medical Helpline at 116117. In an emergency, always call 112.
Units moving to Haartman Hospital
The ear, nose, and throat diseases units moving to the entrance floor of Haartman Hospital are the outpatient clinic that treats tumor patients, and the unit providing urgent care during office hours, where patients arrive with an emergency referral from Meilahti Emergency Department or by separate arrangement.
Haartman Hospital is located at the address Haartmaninkatu 4, in building number 12.
Units moving to Meilahti Bridge Hospital
The Ear, Nose and Throat Diseases Ward K6 will merge with the Oral and Maxillofacial Surgery Ward S7A on the 5th floor of Meilahti Bridge Hospital. The ward’s new name is Head and Neck Surgery Ward S5B. Oral and maxillofacial surgery begins operating in the new premises on Monday, February 3, 2025. The ward's other activities begin on Tuesday, February 4, 2025.
Meilahti Bridge Hospital is located at the address Haartmaninkatu 4, in building number 4. Access to the hospital is via the main entrance to the Meilahti Hospitals.
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m., Fri and eves of public holidays 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
- FIN: Kirurgisen sairaalan toimintoja muuttaa Meilahteen – Korva-, nenä- ja kurkkutautien päivystys siirtyy osaksi Meilahden yhteispäivystystä
- SWE: Delar av verksamheten vid Kirurgiska sjukhusets flyttar till Mejlans – Jouren för öron-, näs- och halssjukdomar flyttar och blir en del av Mejlans samjour
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Genetiska undersökningar kan avslöja orsaken till plötslig oförklarlig död hos unga14.9.2026 09:18:15 EEST | Pressmeddelande
Den bakomliggande orsaken till plötslig oförklarlig död hos unga kan vara en sällsynt ärftlig sjukdom som nödvändigtvis inte kommer fram i vanliga undersökningar. Genetiska undersökningar är en viktig del särskilt i utredningen av plötsliga oväntade dödsfall hos unga. Genetiska undersökningar kan också bidra till att identifiera släktingar som omfattas av risken och förebygga eventuella allvarliga hjärthändelser.
Geenitutkimus voi paljastaa syyn nuoren selittämättömälle äkkikuolemalle14.9.2026 09:18:15 EEST | Tiedote
Nuoren selittämättömän äkkikuoleman taustalla voi olla harvinainen perinnöllinen sairaus, joka ei välttämättä tule esiin tavanomaisissa tutkimuksissa. Geenitutkimus on tärkeä osa erityisesti nuorten odottamattomien äkkikuolemien syyn selvittämisessä. Geenitutkimus voi myös auttaa tunnistamaan riskissä olevia sukulaisia ja ehkäistä mahdollisia vakavia sydäntapahtumia.
Genetic testing may reveal the cause of sudden death in a young person14.9.2026 09:18:15 EEST | Press release
The reason for an unexplained sudden death of a young person may be a rare hereditary disease that can remain undetected in standard examinations. Genetic testing is an important part of investigating the cause of an unexpected sudden death, especially in adolescents. Genetic testing may also help to identify relatives who are at risk of sudden death, and to prevent possible severe cardiac events.
Svår RS-virusinfektion kan öka risken att barnet drabbas av astma i den tidiga barndomen8.9.2026 07:55:55 EEST | Pressmeddelande
En svår RS-virusinfektion i spädbarnsåldern ser ut att öka risken för pipande andning och astma i den tidiga barndomen. I en nyligen publicerad studie identifierades också ett nytt genområde som är förknippat med benägenheten att drabbas av RS-virusinfektion.
Vaikea RSV-infektio voi lisätä lapsen riskiä sairastua astmaan varhaislapsuudessa8.9.2026 07:55:55 EEST | Tiedote
Vauvana sairastettu vakava RSV-infektio näyttää lisäävän hengityksen vinkunan ja astman riskiä varhaislapsuudessa. Vastajulkaistussa tutkimuksessa tunnistettiin myös uusi geenialue, joka liittyy alttiuteen sairastua RSV-infektioon.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom